Subjective assessment of the effects of CNS‐active drugs on sleep by the Leeds sleep evaluation questionnaire: a review

Zisapel, Nava; Laudon, Moshe

doi:10.1002/hup.455

Cited by 52 publications

(37 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinically depressed populations, SSRI use was repeatedly associated with improved subjective sleep. 9,11,22 However, in these previous studies, the improved subjective sleep was possibly biased by the remitting depressive symptoms and more general improvement in mental health. 9,22 Typically these studies focused on the change in sleep quality from start of antidepressant treatment until the end of treatment.…”

Section: Discussionmentioning

confidence: 94%

“…9,11,22 However, in these previous studies, the improved subjective sleep was possibly biased by the remitting depressive symptoms and more general improvement in mental health. 9,22 Typically these studies focused on the change in sleep quality from start of antidepressant treatment until the end of treatment. However, results from studies in healthy participants are still inconsistent with respect to their effect of SSRIs on sleep quality.…”

Section: Discussionmentioning

confidence: 94%

“…However, results from studies in healthy participants are still inconsistent with respect to their effect of SSRIs on sleep quality. 9,11,12,[17][18][19][20][21][22] Our results suggest that SSRI use is associated with better subjective sleep, after we carefully accounted for presence of depressive symptoms, and ruled out possible effect modification by depressive symptoms. We observed a longer total sleep time, better sleep quality, and higher sleep efficiency.…”

Section: Discussionmentioning

confidence: 99%

“…9,11,12,[17][18][19][20][21] Whereas, in clinically depressed patient populations, SSRI use is consistently associated with an improved subjective sleep. 3,9,11,22 The favorable results in depressed populations might represent the improvement of mental health or relief of depressive symptoms. 9,22 So far, most studies focused on subjective perception of sleep as a secondary outcome in clinical trials of antidepressants that are limited by small sample size, short follow-up, or concomitant benzodiazepine use.…”

Section: Introductionmentioning

confidence: 99%

“…3,9,11,22 The favorable results in depressed populations might represent the improvement of mental health or relief of depressive symptoms. 9,22 So far, most studies focused on subjective perception of sleep as a secondary outcome in clinical trials of antidepressants that are limited by small sample size, short follow-up, or concomitant benzodiazepine use. 23 To our knowledge, to date, no population-based study investigated whether SSRIs are associated with better subjective sleep in the middle-aged and elderly population.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Use of Selective Serotonin Reuptake Inhibitors and Sleep Quality: A Population-Based Study

Aarts

Zuurbier

Noordam

et al. 2016

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Study Objectives: Poor sleep is a risk factor for the development and recurrence of depression. Selective serotonin reuptake inhibitor (SSRI) use is consistently associated with good subjective sleep in clinically depressed patient populations. However, studies in the general population are lacking. Our objective was to investigate the association between SSRIs and subjective sleep in a middle-aged and elderly population in a daily practice setting. Methods: We included participants from the prospective Rotterdam Study cohort. Participants had up to two subjective sleep measurements assessed with Pittsburgh Sleep Quality Index ([PSQI], number of measurements = 14,770). SSRI use was based on pharmacy records. We assessed the association between SSRIs and PSQI score and its sub-components, with nonusers of any antidepressant as reference. Analyses were, among others, adjusted for presence of depressive symptoms and concurrent psycholeptic drug use. Results: We included 9,267 participants, average baseline age 66.3 y (standard deviation 10.6), and 57.6% women. SSRI use was significantly associated with a 0.78-point lower PSQI score (95% confidence interval [CI] −1.11; −0.44) which reflects better sleep, compared with non-use. The association was more prominent in continuous SSRI users (−0.71 points, 95% CI −1.18; −0.24). Of the sub-components, SSRIs were associated with 0.70-h longer sleep duration (95% CI 0.56; 0.85), higher sleep quality, higher sleep efficiency, and in contrast more daytime dysfunction. Conclusions: SSRI use was associated with better subjective sleep, after adjustment for depressive symptoms and concurrent psycholeptic drug use. This suggests that, in clinical practice in the middle-aged and elderly population, the sleep quality of some persons may benefit from, continued, SSRI use. Keywords: antidepressive agents, population surveillance, questionnaires, sleep Citation: Aarts N, Zuurbier LA, Noordam R, Hofman A, Tiemeier H, Stricker BH, Visser LE. Use of selective serotonin reuptake inhibitors and sleep quality: a population-based study. J Clin Sleep Med 2016;12(7):989-995. I NTRO DUCTI O NSleep and depression are highly associated. The most common disturbances in the sleep pattern of a depressed person are low sleep efficiency and little deep sleep.1-4 Poor sleep has been shown to be a risk factor for the development or recurrence of depression.2,5-8 However, antidepressant drugs can have positive and negative effects on sleep. 9-13Selective serotonin reuptake inhibitors (SSRIs) are considered as activating antidepressants and a risk factor for poor sleep according to most objective sleep measurements, although sedative properties and daytime somnolence have occasionally been reported for SSRIs. 10,[12][13][14][15][16] Studies in nondepressed individuals regarding the association between SSRIs and subjective sleep reported inconsistent results. 9,11,12,[17][18][19][20][21] Whereas, in clinically depressed patient populations, SSRI use is consistently associated with an improved subjective sle...

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Use of Selective Serotonin Reuptake Inhibitors and Sleep Quality: A Population-Based Study

Aarts

Zuurbier

Noordam

et al. 2016

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis

Crescenzo

Foti

Ciabattini

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Psychostimulants

Howell

Kimmel

2007

Handbook of Contemporary Neuropharmacology

View full text Add to dashboard Cite

Psychstimulants are a broadly defined class of drugs that stimulate the central and peripheral nervous systems as their primary pharmacological effect. The abuse liability of psychostimulants is well established and represents a significant public health concern. An extensive literature documents the critical importance of monoamines (dopamine, serotonin, and norepinephrine) in the behavioral pharmacology and addictive properties of psychostimulants. In particular, dopamine plays a primary role in the reinforcing effects of psychostimulants in animals and humans. However, there is a growing body of evidence that highlights complex interactions among additional neurotransmitter, neuroendocrine, and neuropeptide systems. Cortical glutamatergic systems provide important regulation of dopamine function, and inhibitory amino acid ?‐aminobutyric acid (GABA) systems can modulate basal dopamine and glutamate release. Psychostimulants also activate the hypothalamic‐pituitary axis and thereby engage neuroendocrine systems linked to stress reactivity. Finally, endogenous neuropeptide systems, including opioids and neurotensin, appear to play an important role in the neuropharmacology of psychostimulants. Repeated exposure to psychostimulants can lead to robust and enduring changes in neurobiological substrates and corresponding changes in sensitivity to acute drug effects on neurochemistry and behavior. It is important to emphasize that some neurobiological changes are not evident when drug administration is terminated but actually emerge during the period of drug withdrawal. Significant advances in the understanding of neurobiological mechanisms underlying psychostimulant abuse and dependence have guided pharmacological treatment strategies to improve clinical outcome. In particular, functional agonist treatments may be used effectively to stabilize neurochemistry and behavior. In addition, medications that target glutamatergic and GABAergic function are reasonable candidates that have received significant attention. However, additional clinical studies are required in order to identify safe and efficacious pharmacotherapies.

show abstract

Subjective assessment of the effects of CNS‐active drugs on sleep by the Leeds sleep evaluation questionnaire: a review

Cited by 52 publications

References 108 publications

Use of Selective Serotonin Reuptake Inhibitors and Sleep Quality: A Population-Based Study

Use of Selective Serotonin Reuptake Inhibitors and Sleep Quality: A Population-Based Study

Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis

Psychostimulants

Contact Info

Product

Resources

About